Science

Amy Moore: Biomarker testing can help identify actionable mutations in patients with squamous NSCLC

Amy Moore/LinkedIn

Jan 20, 2025, 16:03

Amy Moore: Biomarker testing can help identify actionable mutations in patients with squamous NSCLC

Amy Moore, Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation, shared a post on LinkedIn about a recent paper by Joshua Reuss et al. published in Lung Cancer Journal:

“Biomarker testing can help identify actionable mutations in patients with squamous NSCLC, especially in those without a history of smoking. Testing is not performed consistently in this population.

“Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smoking”

Authors: Joshua Reuss, Jacob Zaemes, Nishant Gandhi, Phillip Walker, Sandip Patel, Joanne Xiu, Charu Aggarwal, Ari Vanderwalde, Suresh Ramalingam, Balazs Halmos, Stephen Liu.

More posts featuring Amy Moore.

Amy Moore Ari Vanderwalde Balazs Halmos biomarker testing cancer Charu Aggarwal Jacob Zaemes Joanne Xiu Joshua Reuss Nishant Gandhi non small cell lung cancer NSCLC OncoDaily Oncology Phillip Walker Sandip Patel Stephen Liu Suresh Ramalingam

FDA approved sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

Karen Knudsen: Clinical trials are the most advanced form of cancer care

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results